Literature DB >> 29483665

The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?

Natalia Teixeira1, Annemieke van der Hout2, Jan C Oosterwijk2, Janet R Vos3,4, Peter Devilee5, Klaartje van Engelen6, Hanne Meijers-Heijboer7, Rob B van der Luijt8, Mieke Kriege9, Arjen R Mensenkamp4, Matti A Rookus10, Kees E van Roozendaal11, Marian J E Mourits12, Geertruida H de Bock3.   

Abstract

This observational study aimed to investigate whether the reported association between family history (FH) of breast cancer (BC) or ovarian cancer (OC) and OC risks in BRCA1/2 mutation carriers can be explained by mutation position on the gene. In total, 3310 female BRCA1/2 mutation carriers participating in a nationwide prospective cohort (Hereditary Breast and Ovarian Cancer in the Netherlands) were included. FH was classified according to cancer occurrence in first-degree relatives (BC only, OC only, both, neither) and mutations were classified according to their position on the gene (OC cluster region (OCCR), BC cluster region, neither). The main outcome was OC occurrence. Cox proportional-hazard models were applied to investigate the association between FH and OC risks before and after adjusting for mutation position. Of all women included, 202 were diagnosed with OC. A BC-only FH tended to be associated with lower OC risks when compared with a FH without BC/OC (HR: 0.79, 95% CI: 0.52-1.17; HR: 0.59, 95% CI: 0.33-1.07 for BRCA1 and BRCA2, respectively) while an OC-only FH tended to be associated with higher risks (HR: 1.58, 95% CI: 0.90-2.77; HR: 1.75, 95% CI: 0.70-4.37 for BRCA1 and BRCA2, respectively). After adjusting for mutation position, association between FH and OC risks was slightly smaller in magnitude (HR: 0.85, 95% CI: 0.55-1.30; HR: 0.64, 95% CI: 0.34-1.21 for BC-only FH in BRCA1 and BRCA2, respectively; HR: 1.46, 95% CI: 0.80-2.68; HR: 1.49, 95% CI: 0.44-4.02 for OC-only FH in BRCA1 and BRCA2, respectively), indicating that mutation position explains only part of the association. Considering the magnitude of the observed trend, we do not believe FH should be used to change counseling regarding OC prevention.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29483665      PMCID: PMC5974362          DOI: 10.1038/s41431-018-0111-9

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  30 in total

1.  Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.

Authors:  Kelly Metcalfe; Jan Lubinski; Henry T Lynch; Parviz Ghadirian; William D Foulkes; Charmaine Kim-Sing; Susan Neuhausen; Nadine Tung; Barry Rosen; Jacek Gronwald; Peter Ainsworth; Kevin Sweet; Andrea Eisen; Ping Sun; Steven A Narod
Journal:  J Natl Cancer Inst       Date:  2010-11-23       Impact factor: 13.506

Review 2.  Long-term health consequences of premature or early menopause and considerations for management.

Authors:  S S Faubion; C L Kuhle; L T Shuster; W A Rocca
Journal:  Climacteric       Date:  2015-04-07       Impact factor: 3.005

3.  Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.

Authors:  Nasim Mavaddat; Susan Peock; Debra Frost; Steve Ellis; Radka Platte; Elena Fineberg; D Gareth Evans; Louise Izatt; Rosalind A Eeles; Julian Adlard; Rosemarie Davidson; Diana Eccles; Trevor Cole; Jackie Cook; Carole Brewer; Marc Tischkowitz; Fiona Douglas; Shirley Hodgson; Lisa Walker; Mary E Porteous; Patrick J Morrison; Lucy E Side; M John Kennedy; Catherine Houghton; Alan Donaldson; Mark T Rogers; Huw Dorkins; Zosia Miedzybrodzka; Helen Gregory; Jacqueline Eason; Julian Barwell; Emma McCann; Alex Murray; Antonis C Antoniou; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2013-04-29       Impact factor: 13.506

4.  Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene.

Authors:  S A Gayther; J Mangion; P Russell; S Seal; R Barfoot; B A Ponder; M R Stratton; D Easton
Journal:  Nat Genet       Date:  1997-01       Impact factor: 38.330

5.  Variation in cancer risks, by mutation position, in BRCA2 mutation carriers.

Authors:  D Thompson; D Easton
Journal:  Am J Hum Genet       Date:  2001-01-19       Impact factor: 11.025

6.  Ovarian cancer in BRCA1/2 mutation carriers: The impact of mutation position and family history on the cancer risk.

Authors:  Natalia Teixeira; Marian J E Mourits; Janet R Vos; Dorina M van der Kolk; Liesbeth Jansen; Jan C Oosterwijk; Geertruida H de Bock
Journal:  Maturitas       Date:  2015-07-09       Impact factor: 4.342

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

8.  Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation.

Authors:  S A Gayther; W Warren; S Mazoyer; P A Russell; P A Harrington; M Chiano; S Seal; R Hamoudi; E J van Rensburg; A M Dunning; R Love; G Evans; D Easton; D Clayton; M R Stratton; B A Ponder
Journal:  Nat Genet       Date:  1995-12       Impact factor: 38.330

9.  Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.

Authors:  Fergus J Couch; Xianshu Wang; Lesley McGuffog; Andrew Lee; Curtis Olswold; Karoline B Kuchenbaecker; Penny Soucy; Zachary Fredericksen; Daniel Barrowdale; Joe Dennis; Mia M Gaudet; Ed Dicks; Matthew Kosel; Sue Healey; Olga M Sinilnikova; Adam Lee; François Bacot; Daniel Vincent; Frans B L Hogervorst; Susan Peock; Dominique Stoppa-Lyonnet; Anna Jakubowska; Paolo Radice; Rita Katharina Schmutzler; Susan M Domchek; Marion Piedmonte; Christian F Singer; Eitan Friedman; Mads Thomassen; Thomas V O Hansen; Susan L Neuhausen; Csilla I Szabo; Ignacio Blanco; Mark H Greene; Beth Y Karlan; Judy Garber; Catherine M Phelan; Jeffrey N Weitzel; Marco Montagna; Edith Olah; Irene L Andrulis; Andrew K Godwin; Drakoulis Yannoukakos; David E Goldgar; Trinidad Caldes; Heli Nevanlinna; Ana Osorio; Mary Beth Terry; Mary B Daly; Elizabeth J van Rensburg; Ute Hamann; Susan J Ramus; Amanda Ewart Toland; Maria A Caligo; Olufunmilayo I Olopade; Nadine Tung; Kathleen Claes; Mary S Beattie; Melissa C Southey; Evgeny N Imyanitov; Marc Tischkowitz; Ramunas Janavicius; Esther M John; Ava Kwong; Orland Diez; Judith Balmaña; Rosa B Barkardottir; Banu K Arun; Gad Rennert; Soo-Hwang Teo; Patricia A Ganz; Ian Campbell; Annemarie H van der Hout; Carolien H M van Deurzen; Caroline Seynaeve; Encarna B Gómez Garcia; Flora E van Leeuwen; Hanne E J Meijers-Heijboer; Johannes J P Gille; Margreet G E M Ausems; Marinus J Blok; Marjolijn J L Ligtenberg; Matti A Rookus; Peter Devilee; Senno Verhoef; Theo A M van Os; Juul T Wijnen; Debra Frost; Steve Ellis; Elena Fineberg; Radka Platte; D Gareth Evans; Louise Izatt; Rosalind A Eeles; Julian Adlard; Diana M Eccles; Jackie Cook; Carole Brewer; Fiona Douglas; Shirley Hodgson; Patrick J Morrison; Lucy E Side; Alan Donaldson; Catherine Houghton; Mark T Rogers; Huw Dorkins; Jacqueline Eason; Helen Gregory; Emma McCann; Alex Murray; Alain Calender; Agnès Hardouin; Pascaline Berthet; Capucine Delnatte; Catherine Nogues; Christine Lasset; Claude Houdayer; Dominique Leroux; Etienne Rouleau; Fabienne Prieur; Francesca Damiola; Hagay Sobol; Isabelle Coupier; Laurence Venat-Bouvet; Laurent Castera; Marion Gauthier-Villars; Mélanie Léoné; Pascal Pujol; Sylvie Mazoyer; Yves-Jean Bignon; Elżbieta Złowocka-Perłowska; Jacek Gronwald; Jan Lubinski; Katarzyna Durda; Katarzyna Jaworska; Tomasz Huzarski; Amanda B Spurdle; Alessandra Viel; Bernard Peissel; Bernardo Bonanni; Giulia Melloni; Laura Ottini; Laura Papi; Liliana Varesco; Maria Grazia Tibiletti; Paolo Peterlongo; Sara Volorio; Siranoush Manoukian; Valeria Pensotti; Norbert Arnold; Christoph Engel; Helmut Deissler; Dorothea Gadzicki; Andrea Gehrig; Karin Kast; Kerstin Rhiem; Alfons Meindl; Dieter Niederacher; Nina Ditsch; Hansjoerg Plendl; Sabine Preisler-Adams; Stefanie Engert; Christian Sutter; Raymonda Varon-Mateeva; Barbara Wappenschmidt; Bernhard H F Weber; Brita Arver; Marie Stenmark-Askmalm; Niklas Loman; Richard Rosenquist; Zakaria Einbeigi; Katherine L Nathanson; Timothy R Rebbeck; Stephanie V Blank; David E Cohn; Gustavo C Rodriguez; Laurie Small; Michael Friedlander; Victoria L Bae-Jump; Anneliese Fink-Retter; Christine Rappaport; Daphne Gschwantler-Kaulich; Georg Pfeiler; Muy-Kheng Tea; Noralane M Lindor; Bella Kaufman; Shani Shimon Paluch; Yael Laitman; Anne-Bine Skytte; Anne-Marie Gerdes; Inge Sokilde Pedersen; Sanne Traasdahl Moeller; Torben A Kruse; Uffe Birk Jensen; Joseph Vijai; Kara Sarrel; Mark Robson; Noah Kauff; Anna Marie Mulligan; Gord Glendon; Hilmi Ozcelik; Bent Ejlertsen; Finn C Nielsen; Lars Jønson; Mette K Andersen; Yuan Chun Ding; Linda Steele; Lenka Foretova; Alex Teulé; Conxi Lazaro; Joan Brunet; Miquel Angel Pujana; Phuong L Mai; Jennifer T Loud; Christine Walsh; Jenny Lester; Sandra Orsulic; Steven A Narod; Josef Herzog; Sharon R Sand; Silvia Tognazzo; Simona Agata; Tibor Vaszko; Joellen Weaver; Alexandra V Stavropoulou; Saundra S Buys; Atocha Romero; Miguel de la Hoya; Kristiina Aittomäki; Taru A Muranen; Mercedes Duran; Wendy K Chung; Adriana Lasa; Cecilia M Dorfling; Alexander Miron; Javier Benitez; Leigha Senter; Dezheng Huo; Salina B Chan; Anna P Sokolenko; Jocelyne Chiquette; Laima Tihomirova; Tara M Friebel; Bjarni A Agnarsson; Karen H Lu; Flavio Lejbkowicz; Paul A James; Per Hall; Alison M Dunning; Daniel Tessier; Julie Cunningham; Susan L Slager; Chen Wang; Steven Hart; Kristen Stevens; Jacques Simard; Tomi Pastinen; Vernon S Pankratz; Kenneth Offit; Douglas F Easton; Georgia Chenevix-Trench; Antonis C Antoniou
Journal:  PLoS Genet       Date:  2013-03-27       Impact factor: 5.917

10.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

Authors:  Karoline B Kuchenbaecker; John L Hopper; Daniel R Barnes; Kelly-Anne Phillips; Thea M Mooij; Marie-José Roos-Blom; Sarah Jervis; Flora E van Leeuwen; Roger L Milne; Nadine Andrieu; David E Goldgar; Mary Beth Terry; Matti A Rookus; Douglas F Easton; Antonis C Antoniou; Lesley McGuffog; D Gareth Evans; Daniel Barrowdale; Debra Frost; Julian Adlard; Kai-Ren Ong; Louise Izatt; Marc Tischkowitz; Ros Eeles; Rosemarie Davidson; Shirley Hodgson; Steve Ellis; Catherine Nogues; Christine Lasset; Dominique Stoppa-Lyonnet; Jean-Pierre Fricker; Laurence Faivre; Pascaline Berthet; Maartje J Hooning; Lizet E van der Kolk; Carolien M Kets; Muriel A Adank; Esther M John; Wendy K Chung; Irene L Andrulis; Melissa Southey; Mary B Daly; Saundra S Buys; Ana Osorio; Christoph Engel; Karin Kast; Rita K Schmutzler; Trinidad Caldes; Anna Jakubowska; Jacques Simard; Michael L Friedlander; Sue-Anne McLachlan; Eva Machackova; Lenka Foretova; Yen Y Tan; Christian F Singer; Edith Olah; Anne-Marie Gerdes; Brita Arver; Håkan Olsson
Journal:  JAMA       Date:  2017-06-20       Impact factor: 56.272

View more
  2 in total

1.  Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome.

Authors:  Daniele Fanale; Alessia Fiorino; Lorena Incorvaia; Alessandra Dimino; Clarissa Filorizzo; Marco Bono; Daniela Cancelliere; Valentina Calò; Chiara Brando; Lidia Rita Corsini; Roberta Sciacchitano; Luigi Magrin; Alessia Pivetti; Erika Pedone; Giorgio Madonia; Alessandra Cucinella; Giuseppe Badalamenti; Antonio Russo; Viviana Bazan
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 5.738

2.  Clinical Evaluation of BRCA1/2 Mutation in Mexican Ovarian Cancer Patients.

Authors:  Dolores Gallardo-Rincón; Rosa María Álvarez-Gómez; Edgar Montes-Servín; Alfredo Toledo-Leyva; Elizabeth Montes-Servín; David Michel-Tello; Gabriela Alamilla-García; Antonio Bahena-González; Elizabeth Hernández-Nava; Veronica Fragoso-Ontiveros; Raquel Espinosa-Romero; Lucely Cetina-Pérez
Journal:  Transl Oncol       Date:  2019-12-20       Impact factor: 4.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.